Gene expression analyses of palbociclib treated ER+ breast cancer cell lines as assessed by RNA-seq

The goal of this study is to measure gene expression changes resulting over time of palbociclib treatment of T47D, MCF7, and CAMA1 ER+ breast cancer cell lines. Overall design: Examination of gene expression changes in ER+ breast cancer cell lines (T47D, MCF7 and CAMA1) treated with palbociclib for 2, 7, 10 and 14 days. As a control, each of the three cell lines has vehicle treated sub-confluent log phase growing cells for comparison with palbociclib treated cells.